Engineered knottin peptides: A new class of agents for imaging integrin expression in living subjects

Cancer Research

Volumn 69, Issue 6, 2009, Pages 2435-2442

  Kimura, Richard H ^a,b   Cheng, Zhen ^b   Gambhir, Sanjiv Sam ^a,b   Cochran, Jennifer R ^a,c  

^a STANFORD UNIVERSITY   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; INTEGRIN; INTEGRIN BINDING KNOTTIN PEPTIDE; UNCLASSIFIED DRUG; 1,4,7,10-TETRAAZACYCLODODECANE- 1,4,7,10-TETRAACETIC ACID; ARGINYL-GLYCYL-ASPARTIC ACID; ARGINYLGLYCYLASPARTIC ACID; CARBOCYANINE; COPPER; CY5.5 CYANINE DYE; OLIGOPEPTIDE; PEPTIDE; SINGLE HETEROCYCLIC RINGS;

AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; COMPARATIVE STUDY; CONJUGATE; CONTROLLED STUDY; FEMALE; FLUORESCENCE; GLIOBLASTOMA; HUMAN; HUMAN CELL; IC 50; IN VIVO STUDY; LIVER; METABOLITE; MOLECULAR IMAGING; MOUSE; NONHUMAN; OPTICAL RESOLUTION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN ENGINEERING; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN TRANSPORT; XENOGRAFT; ANIMAL; BINDING COMPETITION; BRAIN TUMOR; CHEMISTRY; ENZYME SPECIFICITY; METABOLISM; MOLECULAR GENETICS; NEAR INFRARED SPECTROSCOPY; NUDE MOUSE; SCINTISCANNING; TUMOR CELL LINE;

AMINO ACID SEQUENCE; ANIMALS; BINDING, COMPETITIVE; BRAIN NEOPLASMS; CARBOCYANINES; CELL LINE, TUMOR; COPPER RADIOISOTOPES; GLIOBLASTOMA; HETEROCYCLIC COMPOUNDS, 1-RING; HUMANS; INTEGRINS; MICE; MICE, NUDE; MOLECULAR SEQUENCE DATA; OLIGOPEPTIDES; PEPTIDES; POSITRON-EMISSION TOMOGRAPHY; SPECTROSCOPY, NEAR-INFRARED; SUBSTRATE SPECIFICITY; TRANSPLANTATION, HETEROLOGOUS;

EID: 65549092007     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-2495     Document Type: Article

References (38)

1. Hynes RO. Integrins: versatility, modulation, and signaling in cell adhesion. Cell 1992;69:11-25,
2. Brooks PC, Clark RA, Cheresh DA. Requirement of vascular integrin αvβ3 for angiogenesis. Science 1994;264:569-71.
3. Friedlander M, Brooks PC, Shaffer RW, Kincaid CM, Varner JA, Cheresh DA. Definition of two angiogenic pathways by distinct αv integrins. Science 1995;270:1500-2.
4. Haubner R, Finsinger D, Kessler H. Stereoisomers peptide libaries and peptidomimetics for designing selective inhibitors of the αvβ3 integrin for a new cancer therapy. Angew Chem Int Ed 1997;36:1374-89.
5. Kim S, Bell K, Mousa SA, Varner JA. Regulation of angiogenesis in vivo by ligation of integrin α5β1 with the central cell-binding domain of flbronectin. Am J Pathol 2000;156:1345-62.
6. Alghisi GC, Ruegg C. Vascular integrins in tumor angiogenesis: mediators and therapeutic targets. Endothelium 2006;13:113-35.
7. Mizejewski Gj. Role of integrins in cancer: survey of expression patterns. Proc Soc Exp Biol Med 1999;222:124-38.
8. Stupack DG, Cheresh DA. Integrins and angiogenesis. Curr Top Dev Biol 2004;64:207-38.
9. Curley GP, Blum H, Humphries MJ. Integrin antagonists. Cell Mol Life Sci 1999;56:427-41.
10. Meyer A, Auemheimer J, Modlinger A, Kessler H. Targeting RGD recognizing integrins: drug development, biomaterial research, tumor imaging and targeting. Curr Pharm Des 2006;12:2723-47.
11. Tucker GC. Integrins: molecular targets in cancer therapy. Curr Oncol Rep 2006;8:96-103.
12. Cai W, Gambhir SS, Chen X. Multimodality tumor imaging targeting integrin αvβ3. Biotechniques 2005;39:S6-17.
13. Cai W, Rao J, Gambhir SS, Chen X, How molecular imaging is speeding up antiangiogenic drug development. Mol Cancer Ther 2006;5:2624-33.
14. Haubner R. αvβ3-integrin imaging: a new approach to characterise angiogenesis? Eur J Nucl Med Mol Imaging 2006;33 Suppl 1:54-63.
15. Ruoslahti E. RGD and other recognition sequences for integrins. Annu Rev Cell Dev Biol 1996;12:697-715.
16. Haas TA, Plow EF. Integrin-ligand interactions: a year in review. Curr Opin Cell Biol 1994;6:656-62.
17. l8F]Galacto-RGD identifies the level of integrin αvβ3 expression in man. Clin Cancer Res 2006;12:3942-9.
18. l8F]Galacto-RGD. PLoS Med 2005;2:e70.
19. Hauhner R, Wester HJ, Weber WA, et al. Noninvasive imaging of αvβ3 integrin expression using 18F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res 2001;61:1781-5.
20. Favel A, Mattras H, Coletti-Previero MA, Zwilling R, Robinson EA, Castro B. Protease inhibitors from Ecballium elaterium seeds. Int J Pept Protein Res 1989;33:202-8.
21. Chiche L, Heitz A, Gelly JC, et al. Squash inhibitors: from structural motifs to macrocyclic knottins. Curr Protein Pept Sci 2004;5:341-9.
22. Craik DJ, Clark RJ, Daly NL, Potential therapeutic applications of the cyelotides and related cystine knot mini-proteins. Expert Opin Investig Drugs 2007;16:595-604.
23. Craik DJ, Daly NL, Waine C. The cystine knot motif in toxins and implications for drug design. Toxicon 2001;39:43-60.
24. Maillere B, Mourier G, Herve M, Cotton J, Leroy S, Menez A. Immunogenicity of a disulphide-containing neurotoxin: presentation to T-cells requires a reduction step. Toxicon 1995;33:475-82.
25. Cheng Z, Wu Y, Xiong Z, Gambhir SS, Chen X. Near-infrared fluorescent RGD peptides for optical imaging of integrin αlvβ3 expression in living mice. Bioconjug Chem 2005;16:1433-41.
26. Orlando RA, Cheresh DA. Arginine-glyeine-aspartie acid binding leading to molecular stabilization between integrin αvβ3 and its ligand. J Biol Chem 1991;266:19543-50.
27. 64Cu-labeled tetrameric RGD peptide. J Nucl Med 2005;46:1707-18.
28. Liu S. Radiolabeled multimeric cyclic RGD peptides as integrin αvβ3 targeted radiotracers for tumor imaging. Mol Pharm 2006;3:472-87.
29. Kumar CC, Nie H, Rogers CP, et al. Biochemical characterization of the binding of echistatin to integrin αvβ3 receptor. J Pharmacol Exp Ther 1997;283:843-53.
30. 18F-FRGD2. J Nucl Med 2006;47:113-21.
31. Bruning A, Runnebaum IB. CAR is a cell-cell adhesion protein in human cancer cells and is expres-sionally modulated by dexamethasone, TNFα and TGFβ. Gene Ther 2003;10:198-205.
32. Pfaff M, McLane MA, Beviglia L, Niewiarowski S, Timpl R. Comparison of disintegrins with limited variation in the RGD loop in their binding to purified integrins αIIbβ3, αvβ3, α5βI and in cell adhesion inhibition. Cell Adhes Commun 1994;2:491-501.
33. Pytela R, Pierschhacher MD, Ginsberg MH, Plow EF, Ruoslahti E. Platelet membrane glycoprotein IIb/IIIa: member of a family of Arg-Gly-Asp-specific adhesion receptors. Science 1986;231:1559-62.
34. Iagaru A, Chen X, Gambhir SS. Molecular imaging can accelerate anti-angiogenic drug development and testing. Nat Clin Pract Oncol 2007;4:556-7.
35. 64Cu labeling and PET imaging of brain tumor αvβ3-integrin expression. J Nucl Med 2004;45:1776-83.
36. 64Cu-labeled tetrameric and octameric RGD peptides for small-animal PET of tumor αvβ3 integrin expression, J Nucl Med 2007;48:1162-71.
37. 64Cu-laheled dimeric RGD peptides. Mol Imaging Biol 2004;6:350-9.
38. 64Cu-labeled RGD peptide. Bioconjug Chem 2004;15:41-9.